|
Market Closed -
Nasdaq
16:00:00 2026-10-07 EDT
|
5-day change | 1st Jan Change | ||
| 2.460 USD | -0.40% |
|
-7.52% | +14.95% |
| 09-08 | Veru Advances Oral Sabizabulin into Planned Phase 2 Clinical Trial for Daraxonrasib Resistant Metastatic Pancreatic Cancer | CI |
| 08-10 | Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VERU INC. | Bio Therapeutic Drugs | -0.40% | -7.52% | +14.95% | -43.45% | -97.12% | 42.11M |  | | |
- Stock Market
- Stocks
- VERU Stock
- Charts Veru Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
